Prevention of herpes genitalis by the 'Bulgarian' vaccine F.HSV-2(V)(PRK): Preliminary clinical evidence

Croatian Medical Journal

Volumn 41, Issue 4, 2000, Pages 378-383

  Skinner, Gordon R B ^a   Davies, Judith A ^a   Dundarov, Stefan ^b   Andonov, Peter ^b  

^a Vaccine Research Trust   (United Kingdom)

^b NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

Author keywords

Adjuvants, immunological; Bulgaria; Herpes genitalis; Herpes labialis; HIV; Sex behavior; Sexually transmitted diseases; Vaccine

Indexed keywords

FORMALDEHYDE; HERPES VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANTIGENICITY; ARTICLE; BULGARIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENITAL HERPES; HERPES LABIALIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; KIDNEY CELL; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; RABBIT; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ADOLESCENT; ADULT; ANIMALS; BULGARIA; CRICETINAE; FEMALE; FOLLOW-UP STUDIES; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HUMANS; IMMUNOLOGIC TECHNIQUES; MALE; MIDDLE AGED; RABBITS;

EID: 0034533329     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Limiting the spread of genital herpes
2. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection
3. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals
4. Activation of human immunodeficiency virus by herpesvirus infection: Identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus
5. Effects of long-term Acyclovir chemosuppression on serum IgG antibody to herpes simplex virus
6. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis
7. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis: Report of a prospective double-blind placebo-controlled trial
8. Development of herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use
9. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein
10. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein-B
11. Vaccine potential of a herpes simplex virus type/mutant with an essential glycoprotein deleted
12. Protective vaccination against primary and recurrent disease caused by herpes simplex virus [HSV] type 2 using a genetically disabled HSV-1
13. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8 cytotoxic lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1
14. Double-blind, placebo-controlled trial of HSV type 2 glycoprotein vaccine in persons at high risk for genital herpes infections
15. Early experience with 'antigenoid' vaccine Ac NFU1(S-) MRC towards prevention or modification of herpes genitalis
16. Preparation and immunogenicity of vaccine Ac NFU1(S-) MRC towards the prevention of herpes genitalis
17. A virus-particle vaccine prepared from bovine mammillitis virus against herpes genitalis
18. Development of subunit preparations of cytomegalovirus antigen by aqueous extraction for immunization against cytomegalovirus infection
19. Antigenic differences between strains of herpes simplex virus
20. Preparation and prophylactic-therapeutical effect of Bulgarian inactivated polyvalent Herpes vaccines
21. Characterisation of herpes simplex virus strains isolated from patients with various diseases
22. Immunotherapy with inactivated polyvalent vaccines
23. Seventeen years of application of herpes vaccines in Bulgaria
24. Clinical and immunological effectiveness of different types of herpes vaccines produced in Bulgaria; study on volunteers
25. Design of inactivated polyvalent antiherpes vaccines
26. Serological relatedness of herpes simplex viruses; type-specificity of antibody response
27. Replication of type 2 herpes simplex virus in human endocervical tissue in organ culture
28. The preparation of monoprecipitin antisera to herpes virus specific antigens
29. A sensitive and precise plaque assay for herpes virus
30. Diptheria toxoid. Comparative immunizing value with and without alum, as indicated by Schick test
31. Adjuvants - A balance between toxicity and adjuvanticity
32. The preparation and immunogenicity of vaccine Ac.NFU1(S-) MRC5 towards prevention of herpes genitalis in human subjects
33. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine
34. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: A prospective study
35. A study on the possible oncogenic properties of human herpes viruses
36. The role of herpes virus in cancer of the cervix
37. Cervical cancer: Is herpes simplex virus type II a cofactor?
38. Inactivated vaccines: Characteristics and principles of use
39. Plasmid DNA: A new era in vaccinology
40. Toward clinical trials of DNA vaccines against malaria
41. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
42. One year follow-up of vaccine therapy in HIV-infected immune-deficient individuals: A new strategy
43. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
44. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
45. Novel campaign to test live HIV vaccine